Wird geladen...
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disa...
Gespeichert in:
| Veröffentlicht in: | Mult Scler J Exp Transl Clin |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7079307/ https://ncbi.nlm.nih.gov/pubmed/32206332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320911939 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|